NHD Global
Growth Hormone & IGF · Modified GRF(1-29) research
Scientific Product Dossier
CJC-1295 without DAC is a research peptide related to growth-hormone-releasing hormone. Related short peptides can stimulate the pituitary, a small gland near the brain, to release growth hormone. However, the widely cited studies showing hormone elevation lasting days tested the DAC form, which can bind to blood albumin. Those longer-lasting results cannot be used to describe the without-DAC material. Research planning should first confirm the complete structure and distinguish pathway evidence from activity measured in the actual supplied material.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
In five healthy volunteers, GRF1-29 and longer GRF fragments produced GH peaks 15–30 minutes after an intravenous bolus.
Older pathway context; not a matched trial of commercial “CJC-1295 without DAC.”
Read the primary studyThe multi-day half-life reported for CJC-1295 depends on its albumin-binding drug-affinity-complex design.
Keep the two product families, schemas and evidence summaries separate.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Losa M, et al. Klinische Wochenschrift. 1984. PMID 6240568.
View primary recordRivier J, et al. Annals of the New York Academy of Sciences. 1988. PMID 3133968.
View primary recordThird-party publications selected for direct relevance.
Losa M, et al. Klin Wochenschr. 1984. PMID 6240568.
Rivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
Concise answers for researchers comparing identity, evidence and catalog variants.
Short GRF peptides like GRF1-29 raised growth hormone in healthy volunteers in older studies. That is human evidence for the pathway, not for any catalog product. The long-lasting growth hormone and IGF-I increases came from the DAC form, which binds albumin. Those effects belong to that molecule, not to a without-DAC material. So we know the pathway, but not what any specific without-DAC batch does.
DAC stands for drug-affinity complex, a modification that lets the peptide bind to albumin in blood, keeping it in circulation for days. In a human study, the DAC form of CJC-1295 sustained growth hormone and IGF-I elevation, with an estimated half-life of about 6–8 days. Without DAC, that long-lasting behaviour is not expected. Results from the DAC molecule cannot be transferred to a without-DAC material. These are separate molecules with different behaviour.
No. The DAC form has an albumin-reactive modification that changes persistence and evidence relevance.
The complete sequence, substitutions, terminal form, molecular mass and lot-specific analytical results.
Family-level identifiers organize the catalog. Confirm the supplied form, identity and release criteria using the applicable product specification and ask which lot records are available.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The best-known CJC-1295 human studies tested an albumin-binding DAC construct. A product labeled “CJC-1295 without DAC” lacks that defining feature, so quoting the 5.8–8.1…
Updated October 1, 2026
The phrase “without DAC” tells the reader what is absent, but it may not fully tell them what is present. Reproducible research requires an…
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CND2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
